CO2021000159A2 - Nuevos compuestos y sus composiciones farmacéuticas para el tratamiento de enfermedades - Google Patents
Nuevos compuestos y sus composiciones farmacéuticas para el tratamiento de enfermedadesInfo
- Publication number
- CO2021000159A2 CO2021000159A2 CONC2021/0000159A CO2021000159A CO2021000159A2 CO 2021000159 A2 CO2021000159 A2 CO 2021000159A2 CO 2021000159 A CO2021000159 A CO 2021000159A CO 2021000159 A2 CO2021000159 A2 CO 2021000159A2
- Authority
- CO
- Colombia
- Prior art keywords
- diseases
- treatment
- pharmaceutical compositions
- compounds
- new compounds
- Prior art date
Links
- 201000010099 disease Diseases 0.000 title abstract 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 9
- 150000001875 compounds Chemical class 0.000 title abstract 5
- 238000011282 treatment Methods 0.000 title abstract 3
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 210000000845 cartilage Anatomy 0.000 abstract 2
- 230000006866 deterioration Effects 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 208000023275 Autoimmune disease Diseases 0.000 abstract 1
- 208000011594 Autoinflammatory disease Diseases 0.000 abstract 1
- 208000024172 Cardiovascular disease Diseases 0.000 abstract 1
- 206010010356 Congenital anomaly Diseases 0.000 abstract 1
- 102000014150 Interferons Human genes 0.000 abstract 1
- 108010050904 Interferons Proteins 0.000 abstract 1
- 108090001005 Interleukin-6 Proteins 0.000 abstract 1
- 206010052779 Transplant rejections Diseases 0.000 abstract 1
- 230000002159 abnormal effect Effects 0.000 abstract 1
- 230000033115 angiogenesis Effects 0.000 abstract 1
- 230000008416 bone turnover Effects 0.000 abstract 1
- 230000002124 endocrine Effects 0.000 abstract 1
- 208000030172 endocrine system disease Diseases 0.000 abstract 1
- 230000003176 fibrotic effect Effects 0.000 abstract 1
- 208000027866 inflammatory disease Diseases 0.000 abstract 1
- 229940047124 interferons Drugs 0.000 abstract 1
- 230000036244 malformation Effects 0.000 abstract 1
- 208000030159 metabolic disease Diseases 0.000 abstract 1
- 230000002062 proliferating effect Effects 0.000 abstract 1
- 238000011321 prophylaxis Methods 0.000 abstract 1
- 208000023504 respiratory system disease Diseases 0.000 abstract 1
- 230000007306 turnover Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Pulmonology (AREA)
- Pain & Pain Management (AREA)
- Dermatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
La presente invención describe compuestos de conformidad con la Fórmula I: en donde R1, R2a, X, Y, y Z son como se definen en el presente documento. La presente invención se refiere a compuestos, métodos para su producción, composiciones farmacéuticas que los comprenden, y métodos de tratamiento usando los compuestos, para la profilaxis y/o el tratamiento de enfermedades inflamatorias, enfermedades autoinflamatorias, enfermedades autoinmunitarias, enfermedades proliferativas, enfermedades fibróticas, rechazo de trasplantes, enfermedades que involucran el deterioro del recambio de cartílago, malformación congénita del cartílago, enfermedades que involucran el deterioro del recambio óseo, enfermedades asociadas con la hipersecreción de IL–6, enfermedades asociadas con la hipersecreción de TNF, interferones, IL–12 y/o IL–23, enfermedades respiratorias, enfermedades endocrinas y/o metabólicas, enfermedades cardiovasculares, enfermedades dermatológicas, y/o enfermedades asociadas con la angiogénesis anormal, mediante la administración del compuesto de la invención.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1809836.8A GB201809836D0 (en) | 2018-06-15 | 2018-06-15 | Novel compounds and pharmaceutical compositions thereof for the treatment of diseases |
| GBGB1817344.3A GB201817344D0 (en) | 2018-10-25 | 2018-10-25 | Novel compounds and pharmaceutical compositions thereof for the treatment of diseases |
| PCT/EP2019/063956 WO2019238424A1 (en) | 2018-06-15 | 2019-05-29 | Novel compounds and pharmaceutical compositions thereof for the treatment of diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO2021000159A2 true CO2021000159A2 (es) | 2021-01-18 |
Family
ID=66810768
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CONC2021/0000159A CO2021000159A2 (es) | 2018-06-15 | 2021-01-12 | Nuevos compuestos y sus composiciones farmacéuticas para el tratamiento de enfermedades |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20220402911A1 (es) |
| EP (1) | EP3806853A1 (es) |
| JP (1) | JP7399116B2 (es) |
| KR (1) | KR20210022055A (es) |
| CN (1) | CN112292129B (es) |
| AU (1) | AU2019286162A1 (es) |
| BR (1) | BR112020025202A2 (es) |
| CA (1) | CA3103304A1 (es) |
| CO (1) | CO2021000159A2 (es) |
| IL (1) | IL279397B2 (es) |
| MA (1) | MA52873A (es) |
| MX (1) | MX2020013275A (es) |
| PH (1) | PH12020552160A1 (es) |
| SG (1) | SG11202012458RA (es) |
| TW (1) | TW202015677A (es) |
| WO (1) | WO2019238424A1 (es) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201907558D0 (en) * | 2019-05-29 | 2019-07-10 | Galapagos Nv | Novel compounds and pharmaceutical compositions thereof for the treatment of diseases |
| US10702525B1 (en) * | 2019-09-04 | 2020-07-07 | United Arab Emirates University | Pyrimidine derivatives as anti-diabetic agents |
| WO2022174253A1 (en) * | 2021-02-12 | 2022-08-18 | Nimbus Saturn, Inc. | Hpk1 antagonists and uses thereof |
| WO2023239941A1 (en) * | 2022-06-10 | 2023-12-14 | Interline Therapeutics Inc. | Imidazo(1,2-a)pyridine derivatives as ripk2 inhibitors |
| US20240124450A1 (en) * | 2022-09-21 | 2024-04-18 | Pfizer Inc. | Novel SIK Inhibitors |
| WO2024104441A1 (en) * | 2022-11-17 | 2024-05-23 | Insilico Medicine Ip Limited | Salt-inducible kinases (sik) inhibitors and methods of uses thereof |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EA201270566A1 (ru) * | 2009-10-16 | 2012-11-30 | Риб-Экс Фармасьютикалз, Инк. | Противомикробные соединения и способы их получения и применения |
| US9260426B2 (en) * | 2012-12-14 | 2016-02-16 | Arrien Pharmaceuticals Llc | Substituted 1H-pyrrolo [2, 3-b] pyridine and 1H-pyrazolo [3, 4-b] pyridine derivatives as salt inducible kinase 2 (SIK2) inhibitors |
| JP6720355B2 (ja) * | 2015-06-24 | 2020-07-08 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | ヘテロアリール置換のアミノピリジン化合物 |
| CN106496222A (zh) | 2016-09-07 | 2017-03-15 | 华东师范大学 | 一种咪唑并[1,2‑a]吡啶化合物及其制备方法和应用 |
-
2019
- 2019-05-29 BR BR112020025202-6A patent/BR112020025202A2/pt unknown
- 2019-05-29 WO PCT/EP2019/063956 patent/WO2019238424A1/en unknown
- 2019-05-29 CA CA3103304A patent/CA3103304A1/en active Pending
- 2019-05-29 MA MA052873A patent/MA52873A/fr unknown
- 2019-05-29 EP EP19729465.5A patent/EP3806853A1/en active Pending
- 2019-05-29 AU AU2019286162A patent/AU2019286162A1/en active Pending
- 2019-05-29 SG SG11202012458RA patent/SG11202012458RA/en unknown
- 2019-05-29 IL IL279397A patent/IL279397B2/en unknown
- 2019-05-29 US US17/252,146 patent/US20220402911A1/en active Pending
- 2019-05-29 CN CN201980039729.0A patent/CN112292129B/zh active Active
- 2019-05-29 MX MX2020013275A patent/MX2020013275A/es unknown
- 2019-05-29 JP JP2020569833A patent/JP7399116B2/ja active Active
- 2019-05-29 KR KR1020217001276A patent/KR20210022055A/ko not_active Application Discontinuation
- 2019-06-03 TW TW108119121A patent/TW202015677A/zh unknown
-
2020
- 2020-12-14 PH PH12020552160A patent/PH12020552160A1/en unknown
-
2021
- 2021-01-12 CO CONC2021/0000159A patent/CO2021000159A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| SG11202012458RA (en) | 2021-01-28 |
| TW202015677A (zh) | 2020-05-01 |
| JP7399116B2 (ja) | 2023-12-15 |
| CA3103304A1 (en) | 2019-12-19 |
| PH12020552160A1 (en) | 2021-06-28 |
| JP2021527106A (ja) | 2021-10-11 |
| CN112292129B (zh) | 2024-04-19 |
| AU2019286162A1 (en) | 2021-02-04 |
| BR112020025202A2 (pt) | 2021-03-09 |
| KR20210022055A (ko) | 2021-03-02 |
| IL279397A (en) | 2021-01-31 |
| WO2019238424A1 (en) | 2019-12-19 |
| MA52873A (fr) | 2021-04-21 |
| MX2020013275A (es) | 2021-02-18 |
| IL279397B1 (en) | 2023-11-01 |
| IL279397B2 (en) | 2024-03-01 |
| CN112292129A (zh) | 2021-01-29 |
| US20220402911A1 (en) | 2022-12-22 |
| EP3806853A1 (en) | 2021-04-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2021000159A2 (es) | Nuevos compuestos y sus composiciones farmacéuticas para el tratamiento de enfermedades | |
| CO2020008066A2 (es) | Nuevos compuestos y sus composiciones farmacéuticas para el tratamiento de enfermedades | |
| CL2021003133A1 (es) | Nuevos compuestos y sus composiciones farmacéuticas para el tratamiento de enfermedades. | |
| CO2020005200A2 (es) | Compuestos novedosos y composiciones farmaceuticas de los mismos para el tratamiento de trastornos inflamatorios | |
| DOP2017000139A (es) | Nuevos compuestos y composiciones farmacéuticas de los mismos para el tratamiento de desórdenes inflamatorios y oesteoartritis | |
| CO2020000056A2 (es) | Nuevos compuestos y composiciones farmacéuticas de los mismos para el tratamiento de la fibrosis | |
| CU24564B1 (es) | 2-heteroaril-3-oxo-2,3-dihidropiridazin-4-carboxamidas | |
| UY35985A (es) | Composiciones farmacéuticas para el tratamiento de trastornos inflamatorios. | |
| CO2017011093A2 (es) | Derivados de 6,7-dihidropirido [2,1-a]isoquinolin-2-ona como antagonistas del receptor gpr84, y composiciones que los contienen | |
| ECSP14001627A (es) | Procedimiento de preparación de 5-fluoro-1h-pirazolopiridinas sustituidas | |
| AR089960A1 (es) | Compuesto de imidazolopiridina para el tratamiento de enfermedades degenerativas e inflamatorias | |
| SG11201907909TA (en) | Fgfr inhibitor and application thereof | |
| BR112017025309A2 (pt) | micro-organismos geneticamente modificados para a fabricação de produtos derivados de corismato | |
| CO2018009876A2 (es) | Nuevos compuestos y sus composiciones farmacéuticas para el tratamiento de fibrosis | |
| PH12016501677B1 (en) | Benzimidazole derivatives and pharmaceutical compositions thereof for the treatment of inflammatory disorders | |
| AR122929A1 (es) | Nuevos compuestos y sus composiciones farmacéuticas para el tratamiento de enfermedades | |
| BR112018075415A2 (pt) | composição mastigável macia compreendendo plantago | |
| BR112022012130A2 (pt) | Compostos antelmínticos compreendendo uma estrutura azaindólica | |
| AR119745A1 (es) | Compuestos y composiciones farmacéuticas de los mismos para el tratamiento de enfermedades | |
| AR106384A1 (es) | Derivados de 6-[5-amino-6-(2-etoxietoxi)-imidazo[4,5-b]piridin-3-il]-nicotinonitrilo como inhibidores irak | |
| SA520412289B1 (ar) | مركبات مثبط الهدف الميكانيكي للراباميسين | |
| CO2021014223A2 (es) | Nuevos compuestos y composiciones farmacéuticas de los mismos para el tratamiento de trastornos inflamatorios | |
| PH12019501853A1 (en) | Novel compositions and pharmaceutical compositions thereof for the treatment of inflammatory disorders | |
| GB201914498D0 (en) | An anhydrous pharmaceutical composition for maintenance treatment of psoriasis | |
| MX2021010093A (es) | Derivados de pirazolopiridina como inhibidores serina/treonina cinasa que contiene el dominio per-arnt-sim (pask). |